Replies to post #397352 on Innovation Pharmaceuticals Inc (IPIX)

[leavetheguntakethecannolis]

Still not "dead" as we have been told. Awesome news frenchbroad.

[TheHound]

No one is buying it. Dead.

[zandant]

Wow. The market must be aware of this gem otherwise there would be zero intead of 1.8 thousand in volume today.

[loanranger]

There are links in the paper that are very interesting. Specifically, while much is made of a paper having been peer reviewed I'm not accustomed to seeing the actual peer reviews published. In this case they were.

Scroll down to "Supplementary information" and click on Peer Review File.

[williamssc]

Positive peer review. B likely to improve outcomes when combined with other drugs. BRI combined with CAS significantly clears A. fumigatus lung infection in an immunosuppressed murine model of invasive pulmonary aspergillosis.

BRI alone also decreases A. fumigatus fungal burden and ablates disease development in a murine model of fungal keratitis. Our results indicate that combinations of BRI and antifungal drugs in clinical use are likely to improve the treatment outcome of aspergillosis and other fungal infections.

Taken together, these results indicate that BRI is able to potentiate CAS activity for different human fungal pathogens, including C. neoformans. Interestingly, C. neoformans is very sensitive to BRI alone and BRI is fungicidal against this fungus. Thus, BRI is an alternative therapeutic against C. neoformans alone or in combination with CAS since it potentiates the latter’s activity into a fungicidal drug. BRI?+?CAS combination has also synergism against C. auris dramatically decreasing its viability.

Great find frenchbroad.

[MackG]

You have again demonstrated IPIX is far from dead!

[SitTight]

This Nature publication is amazing news! It validates Brilacidin once more.

I trust you forwarded this to your European company contacts? The meeting is probably this week or next, so this should be an interesting topic in their discussions.

[Brinjal]

Thank you for sharing this. To see Brilacidin being mentioned in nature.com, a premier science publication, is a milestone in itself!